Medicine and Dentistry
Neoplasm
100%
Lung Cancer
91%
Surgery
79%
Non Small Cell Lung Cancer
77%
Malignant Neoplasm
72%
Overall Survival
54%
Chemoradiotherapy
53%
Esophageal Cancer
52%
Diseases
42%
Radiation Therapy
35%
Adenocarcinoma
33%
Esophagectomy
33%
Thorax Surgery
30%
Recurrent Disease
30%
Lung
29%
Pneumonectomy
28%
Metastatic Carcinoma
27%
Esophageal Adenocarcinoma
24%
Cancer
24%
Cancer Cell
22%
Pleura Mesothelioma
21%
Surgeon
20%
Esophagus
20%
Lung Metastasis
18%
Hazard Ratio
16%
Lobectomy
16%
Cancer Staging
16%
Protein P53
16%
Programmed Cell Death
16%
Carcinoma
14%
Gastroesophageal Junction
13%
Mesothelioma
13%
Esophagus Carcinoma
12%
Clinical Trial
12%
Lymph Node
12%
Disease Free Survival
12%
Computer Assisted Tomography
12%
Gene Therapy
12%
Epidermal Growth Factor Receptor
11%
Primary Tumor
11%
Adenoviridae
11%
Survival Rate
11%
Neoadjuvant Therapy
11%
Induction Chemotherapy
10%
Odds Ratio
10%
Long Term Survival
10%
Squamous Cell Carcinoma
10%
In Vitro
10%
Promoter Region
10%
Prognostic Factor
10%
positron emission tomographic scan
10%
Non-Small Cell Lung Cancer
9%
Multivariate Analysis
9%
Clinical Stage
9%
Lung Adenocarcinoma
8%
Metastasectomy
8%
Biological Marker
8%
Proportional Hazards Model
8%
Intensity Modulated Radiation Therapy
8%
Tumor Cell
8%
Tumor Suppressor Gene
8%
Prostate Cancer
8%
Tumor Progression
8%
Soft Tissue Sarcoma
8%
Thoracotomy
7%
Progression Free Survival
7%
Cancer Surgery
7%
Thoracic Wall
7%
Cardiothoracics
7%
Adenovirus Vector
7%
Breast Cancer
7%
Surgical Technique
7%
Distant Metastasis
7%
Abdominal Cancer
7%
Barrett Esophagus
7%
Gene Expression
7%
Immunotherapy
7%
Lymph Node Metastasis
7%
Connective Tissue Cancer
7%
Positron Emission Tomography-Computed Tomography
6%
Neoadjuvant Chemotherapy
6%
Endoscopic Ultrasound
6%
Preoperative Chemotherapy
6%
Xenograft
6%
Health Care Cost
6%
Melanoma
6%
Oncogene
6%
Gene Transfer
6%
Lung Tumor
6%
Postoperative Complication
6%
Carcinogenesis
6%
Biopsy Technique
6%
Colorectal Carcinoma
6%
Small Cell Lung Cancer
5%
Lymphocyte
5%
Diagnosis
5%
Cisplatin
5%
Recurrence Free Survival
5%
Immunity
5%
Adjuvant Therapy
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
58%
Tumor
42%
Esophageal Cancer
38%
Lung Cancer
38%
Overall Survival
37%
Chemotherapy
22%
Esophageal Adenocarcinoma
21%
Adenocarcinoma
17%
Adenovirus
17%
Apoptosis
17%
Resection
16%
Confidence Interval
15%
Esophagectomy
14%
Gene Therapy
14%
Malignant Pleural Mesothelioma
13%
Combined Modality Therapy
13%
Cancer Cells
13%
Pathological Complete Response
13%
Esophageal Squamous Cell Carcinoma
12%
Cancer Patients
12%
Chemoradiation
11%
In Cancer
11%
Hazard Ratio
11%
Preoperative Chemoradiation
11%
Disease-free Survival
11%
Wild-type p53
10%
Early-stage Lung Cancer
10%
Lung
10%
Gene Transfer
10%
Surgical Resection
10%
Squamous Cell Carcinoma (SqCC)
9%
Adenoviral
9%
Induction Chemotherapy
9%
Radiation Therapy
9%
Overexpression
9%
Chemoradiotherapy
9%
Adenoviral Vector
9%
Radiotherapy
9%
Induced Apoptosis
9%
Pulmonary Metastasis
8%
Lung Cancer Cells
8%
Tumor Suppressor Gene
8%
P53 Gene
8%
Neoadjuvant Chemoradiotherapy (nCRT)
8%
Non-small Cell Lung Cancer Cells
8%
Mesothelioma
8%
Tumor Cells
7%
Esophageal Carcinoma
7%
Metastasis
7%
Clinical Trials
7%
5-year Survival
7%
International Association for the Study of Lung Cancer (IASLC)
7%
Clinical Outcomes
7%
Stereotactic Ablative Radiotherapy
7%
Neoadjuvant
7%
Progression-free Survival
7%
Cisplatin
7%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
6%
Neoadjuvant Chemotherapy
6%
Primary Tumor
6%
Resectable Lung Cancer
6%
Apoptosis Induction
6%
Gene Expression
6%
Positron Emission Tomography
6%
Neoadjuvant Therapy
6%
Pathological Response
6%
Multivariate Analysis
6%
Survival Prediction
6%
Prostate Cancer
6%
Risk Factors
6%
Odds Ratio
6%
Pathological Stage
6%
Wild-type p53 Gene
6%
Lung Adenocarcinoma
6%
Tumor Growth
6%
Computed Tomography
6%
Concurrent Chemoradiotherapy
6%
Stage I Lung Cancer
6%
Median Overall Survival
6%
Pathologic
5%
Gastroesophageal Junction
5%
Preoperative Chemotherapy
5%
Long-term Survival
5%
Tumor Protein p53 (TP53)
5%
TP53 mutation
5%
Advanced Esophageal Cancer
5%
Lobectomy
5%
Lung Cancer Patients
5%
Distant Metastasis
5%
Adenocarcinoma of the Esophagogastric Junction
5%
Thoracic Surgery
5%
Locoregional Recurrence
5%
Gastric Cancer
5%
Oncogene
5%
Barrett's Esophagus
5%
Tumor Size
5%
Patient Selection
5%
Histology
5%
Locally Advanced
5%
Definitive Chemoradiation
5%